Vor Biopharma Inc. (VOR) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Vor Biopharma Inc. (NASDAQ: VOR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $20.91 (+1.26% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VOR ranks #375 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TSHA (Taysha Gene Therapies Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and IMTX (Immatics N.V.) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.09B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).
Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $0 in revenue, -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 71% of 52W Range • RSI-14 at 57.3 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While VOR currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.70) and Max Pain ($21.96) forces dealer call-delta covering toward $28.10.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Vor Biopharma Inc. (VOR) advanced +1.26% to $20.91, trading at 71% of its 52-week range ($6.5 – $26.76). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 regi
https://www.sec.gov/Archives/edgar/data/1817229/000119312526439975/d180165d424b5.htm
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001) 89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively Prote
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines,
William Blair analyst Myles Minter initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Outperform rating.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VOR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VOR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Vor Biopharma Inc. (VOR) ranks #375 by composite RQD confidence (46/100, grade D) and #335 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, VOR leads on earnings valuation at N/A trailing P/E, while VOR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with VOR at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VOR
ACTIVE
Vor Biopharma Inc. | D | 46/100 | — | — | -35.0% | +1.26% | $1.24B | Benchmark Subject |
| TSHA Taysha Gene Therapies Inc. | E | 33/100 | — | — | -35.0% | -0.24% | $1.38B | /tsha-vs-vor → |
| IMTX Immatics N.V. | D | 45/100 | — | — | — | -0.54% | $1.09B | /imtx-vs-vor → |
| INBX Inhibrx Biosciences Inc. | E | 18/100 | — | — | -35.0% | +0.49% | $1.08B | /inbx-vs-vor → |
| LYCA Lycia Therapeutics Inc. | C- | 59/100 | — | — | — | +10.70% | $1.44B | /lyca-vs-vor → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vor Biopharma Inc. (VOR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$696.0M, operating cash flow of -$142.7M, and free cash flow of -$143.7M (-43.8% YoY). On the balance sheet, VOR closed FY2025 with $464.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$696.0M | -$142.7M | -$143.7M | $464.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$116.9M | -$99.7M | -$99.9M | $142.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$117.9M | -$100.3M | -$100.3M | — | — |
As of 2026-11-02, Vor Biopharma Inc. (NASDAQ: VOR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $20.91 (+1.26% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VOR ranks #375 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VOR carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TSHA (Taysha Gene Therapies Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and IMTX (Immatics N.V.) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.09B). Among the 5-stock peer group, VOR leads on earnings multiple (N/A) while VOR leads on capital efficiency (-35.0% ROIC).
Per VOR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817229), Vor Biopharma Inc. generated $0 in revenue, -$696.0M in net income, and -$143.7M in free cash flow against $464.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VOR last traded at $20.91 (+1.26% on volume of 968,264 shares), positioning the stock +1.01% above its 50-day simple moving average ($20.70) and +20.38% above its 200-day simple moving average ($17.37). Across its 52-week range of $6.50 to $26.76, VOR sits at the 71.1% percentile with a 14-day RSI of 57.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($18.30 to $23.52).
Why VOR Stock advanced +1.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).